Short answer
GLAUKOS Corp (GKOS) filed its Q2 2026 10-Q quarterly report on Jul 29, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $186M (up 49.5% year over year) with net income of −$18M.
Q2 2026 key financials · XBRL
- Revenue
- $186M
- +49.5% YoY · +23.3% QoQ
- Net income
- −$18M
- +6.5% YoY · +7.1% QoQ
- Operating margin
- -9.3%
- Gross margin
- 81.7%
- EPS (diluted)
- −$0.31
- +8.8% YoY · +8.8% QoQ
Source: XBRL data from the GLAUKOS Corp (GKOS) Q2 2026 10-Q on SEC EDGAR. USD.
GLAUKOS Corp Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly triggered risk: Huntsville, Alabama facility construction anticipated to require more than $80.0 million in capital expenditures beginning in 2026
- Most material operational risk: iDose TR and Epioxa sales carry extended terms, driving a $31.9 million accounts-receivable increase
- Regulatory and compliance risk: Germany reimbursement challenges partially offset international glaucoma sales growth
- Near-term market risk: Epioxa customer transition contributed to a modest decrease in U.S. Photrexa sales
- Financial risk: Foreign-currency movements on intercompany loans reduced six-month non-operating income to $0.1 million from $6.1 million
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other GLAUKOS Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.